REGENERON PHARMACEUTICALS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that REGENERON PHARMACEUTICALS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $1.58B | Feb 8, 2018 |
| FY2017 | Sep 30, 2017 | $1.50B | Feb 8, 2018 |
| FY2017 | Jun 30, 2017 | $1.47B | Feb 8, 2018 |
| FY2017 | Mar 31, 2017 | $1.32B | Feb 8, 2018 |
| FY2017 | Dec 31, 2016 | $1.23B | Feb 8, 2018 |
| FY2017 | Sep 30, 2016 | $1.22B | Feb 8, 2018 |
| FY2017 | Jun 30, 2016 | $1.21B | Feb 8, 2018 |
| FY2017 | Mar 31, 2016 | $1.20B | Feb 8, 2018 |
| FY2016 | Dec 31, 2015 | $1.10B | Feb 9, 2017 |
| FY2016 | Sep 30, 2015 | $1.14B | Feb 9, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.34B | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $14.20B | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | $13.12B | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | $12.17B | Feb 5, 2025 |
| FY2023 | Dec 31, 2021 | $16.07B | Feb 5, 2024 |
| FY2020 | Dec 31, 2020 | $2.42B | Feb 8, 2021 |
| FY2020 | Sep 30, 2020 | $2.29B | Feb 8, 2021 |
| FY2020 | Jun 30, 2020 | $1.95B | Feb 8, 2021 |
| FY2020 | Mar 31, 2020 | $1.83B | Feb 8, 2021 |
| FY2020 | Dec 31, 2019 | $1.86B | Feb 8, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.50B | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $4.41B | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | $3.95B | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | $4.34B | Feb 5, 2025 |
| FY2023 | Dec 31, 2021 | $8.08B | Feb 5, 2024 |
| FY2020 | Dec 31, 2020 | $1.15B | Feb 8, 2021 |
| FY2020 | Sep 30, 2020 | $842.10M | Feb 8, 2021 |
| FY2020 | Jun 30, 2020 | $897.30M | Feb 8, 2021 |
| FY2020 | Mar 31, 2020 | $624.60M | Feb 8, 2021 |
| FY2020 | Dec 31, 2019 | $792.00M | Feb 8, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.58B | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $3.99B | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | $4.05B | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | $4.74B | Feb 5, 2025 |
| FY2023 | Dec 31, 2021 | $8.95B | Feb 5, 2024 |
| FY2022 | Dec 31, 2020 | $3.58B | Feb 6, 2023 |
| FY2021 | Dec 31, 2019 | $2.21B | Feb 7, 2022 |
| FY2020 | Dec 31, 2018 | $2.53B | Feb 8, 2021 |
| FY2019 | Dec 31, 2017 | $2.08B | Feb 7, 2020 |
| FY2018 | Dec 31, 2016 | $1.33B | Feb 7, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.85B | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $5.13B | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | $4.44B | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | $3.59B | Feb 5, 2025 |
| FY2023 | Dec 31, 2021 | $2.86B | Feb 5, 2024 |
| FY2022 | Dec 31, 2020 | $2.65B | Feb 6, 2023 |
| FY2021 | Dec 31, 2019 | $2.45B | Feb 7, 2022 |
| FY2020 | Dec 31, 2018 | $1.47B | Feb 8, 2021 |
| FY2019 | Dec 31, 2017 | $2.08B | Feb 7, 2020 |
| FY2018 | Dec 31, 2016 | $2.05B | Feb 7, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.70B | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $2.95B | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | $2.63B | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | $2.12B | Feb 5, 2025 |
| FY2023 | Dec 31, 2021 | $1.82B | Feb 5, 2024 |
| FY2022 | Dec 31, 2020 | $1.35B | Feb 6, 2023 |
| FY2021 | Dec 31, 2019 | $1.34B | Feb 7, 2022 |
| FY2020 | Dec 31, 2018 | $1.13B | Feb 8, 2021 |
| FY2019 | Dec 31, 2017 | $1.32B | Feb 7, 2020 |
| FY2018 | Dec 31, 2016 | $1.18B | Feb 7, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.98B | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $4.42B | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | $4.59B | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | $5.01B | Feb 5, 2025 |
| FY2023 | Dec 31, 2021 | $7.08B | Feb 5, 2024 |
| FY2022 | Dec 31, 2020 | $2.62B | Feb 6, 2023 |
| FY2021 | Dec 31, 2019 | $2.43B | Feb 7, 2022 |
| FY2020 | Dec 31, 2018 | $2.20B | Feb 8, 2021 |
| FY2019 | Dec 31, 2017 | $1.31B | Feb 7, 2020 |
| FY2018 | Dec 31, 2016 | $1.49B | Feb 7, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $40.56B | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $37.76B | Feb 4, 2026 |
| FY2024 | Dec 31, 2023 | $33.08B | Feb 5, 2025 |
| FY2023 | Dec 31, 2022 | $29.21B | Feb 5, 2024 |
| FY2022 | Dec 31, 2021 | $25.43B | Feb 6, 2023 |
| FY2021 | Dec 31, 2020 | $17.16B | Feb 7, 2022 |
| FY2020 | Dec 31, 2019 | $14.81B | Feb 8, 2021 |
| FY2019 | Dec 31, 2018 | $11.73B | Feb 7, 2020 |
| FY2018 | Dec 31, 2017 | $8.76B | Feb 7, 2019 |
| FY2017 | Dec 31, 2016 | $6.97B | Feb 8, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.30B | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $8.41B | Feb 4, 2026 |
| FY2024 | Dec 31, 2023 | $7.11B | Feb 5, 2025 |
| FY2023 | Dec 31, 2022 | $6.55B | Feb 5, 2024 |
| FY2022 | Dec 31, 2021 | $6.67B | Feb 6, 2023 |
| FY2021 | Dec 31, 2020 | $6.14B | Feb 7, 2022 |
| FY2020 | Dec 31, 2019 | $3.72B | Feb 8, 2021 |
| FY2019 | Dec 31, 2018 | $2.98B | Feb 7, 2020 |
| FY2018 | Dec 31, 2017 | $2.62B | Feb 7, 2019 |
| FY2017 | Dec 31, 2016 | $2.52B | Feb 8, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $31.26B | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $29.35B | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | $25.97B | Feb 4, 2026 |
| FY2025 | Dec 31, 2022 | $22.66B | Feb 4, 2026 |
| FY2024 | Dec 31, 2021 | $18.77B | Feb 5, 2025 |
| FY2023 | Dec 31, 2020 | $11.03B | Feb 5, 2024 |
| FY2022 | Dec 31, 2019 | $11.09B | Feb 6, 2023 |
| FY2021 | Dec 31, 2018 | $8.76B | Feb 7, 2022 |
| FY2020 | Dec 31, 2017 | $6.14B | Feb 8, 2021 |
| FY2019 | Dec 31, 2016 | $4.45B | Feb 7, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $35.80B | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $31.67B | Feb 4, 2026 |
| FY2024 | Dec 31, 2023 | $27.26B | Feb 5, 2025 |
| FY2023 | Dec 31, 2022 | $23.31B | Feb 5, 2024 |
| FY2022 | Dec 31, 2021 | $18.97B | Feb 6, 2023 |
| FY2021 | Dec 31, 2020 | $10.89B | Feb 7, 2022 |
| FY2020 | Dec 31, 2019 | $7.38B | Feb 8, 2021 |
| FY2019 | Dec 31, 2018 | $5.25B | Feb 7, 2020 |
| FY2018 | Dec 31, 2017 | $2.95B | Feb 7, 2019 |
| FY2017 | Dec 31, 2016 | $1.75B | Feb 8, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.12B | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $2.49B | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | $2.73B | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | $3.11B | Feb 5, 2025 |
| FY2023 | Dec 31, 2021 | $2.89B | Feb 5, 2024 |
| FY2022 | Dec 31, 2020 | $2.19B | Feb 6, 2023 |
| FY2021 | Dec 31, 2019 | $1.62B | Feb 7, 2022 |
| FY2020 | Dec 31, 2018 | $1.47B | Feb 8, 2021 |
| FY2019 | Dec 31, 2017 | $812.70M | Feb 7, 2020 |
| FY2018 | Dec 31, 2016 | $535.20M | Feb 7, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 43 | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | 40 | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | 37 | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | 40 | Feb 5, 2025 |
| FY2023 | Dec 31, 2021 | 76 | Feb 5, 2024 |
| FY2020 | Dec 31, 2020 | 10 | Feb 8, 2021 |
| FY2020 | Sep 30, 2020 | 7 | Feb 8, 2021 |
| FY2020 | Jun 30, 2020 | 8 | Feb 8, 2021 |
| FY2020 | Mar 31, 2020 | 5 | Feb 8, 2021 |
| FY2020 | Dec 31, 2019 | 7 | Feb 8, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 41 | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | 38 | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | 34 | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | 38 | Feb 5, 2025 |
| FY2023 | Dec 31, 2021 | 71 | Feb 5, 2024 |
| FY2020 | Dec 31, 2020 | 10 | Feb 8, 2021 |
| FY2020 | Sep 30, 2020 | 7 | Feb 8, 2021 |
| FY2020 | Jun 30, 2020 | 7 | Feb 8, 2021 |
| FY2020 | Mar 31, 2020 | 5 | Feb 8, 2021 |
| FY2020 | Dec 31, 2019 | 6 | Feb 8, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2011 | Dec 31, 2011 | 90.69M | Feb 21, 2012 |
| FY2010 | Dec 31, 2010 | 87.24M | Feb 17, 2011 |
| FY2010 | Dec 31, 2009 | 78.86M | Feb 17, 2011 |